Skip to main content
OpenTrials
Completed

NCT Number: NCT04466241

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

In January 2020, the new SARS-CoV-2 coronavirus was identified in China. The disease caused by this coronavirus was named COVID-19 by the World Health Organization (WHO). Since March 11, 2020, the WHO has described the global situation of COVID-19 as a pandemic. In Côte d'Ivoire, as in other African countries, the number of cases is increasing exponentially.

Coronaviruses are a family of viruses that cause illnesses ranging from the common cold to more severe pathologies. COVID-19 can result in fever or a feeling of fever (chills, hot-cold), cough, headache, aches and pains, unusual tiredness, sudden loss of smell, total disappearance of taste, or diarrhea. In severe forms, respiratory difficulties can lead to hospitalization in intensive care or even death.

Numerous studies are currently being conducted around the world to seek effective treatment, but few of them have started specifically in Africa. Moreover, most of these studies are using a single drug to control the infection, whether these are repositioned drugs, i.e. already being used for other diseases, or other newer drugs.

Currently in Côte d'Ivoire, the preferred treatment for COVID-19 is an antiviral: lopinavir/ritonavir (LPV/r), usually directed against the Human Immunodeficiency Virus (HIV).

Since the number of viruses (viral load) is high in the respiratory tract during COVID-19 infection, we propose in INTENSE-COV (ICOV) clinical trial to study whether the combination of two drugs is more effective than taking a single drug on reducing the viral load in the respiratory tract but also on reducing inflammation.

These drugs include the LPV/r already in use in Côte d'Ivoire as well as an antihypertensive drug - telmisartan, and a drug that lowers blood cholesterol - atorvastatin. All three have been known for a long time and have been shown to be effective against other viruses. In addition, they are generic, inexpensive and readily available in all countries.

The objectives of the ICOV study are therefore to improve viral eradication from the patient's body and respiratory tract, to reduce inflammation, to improve more rapidly the patient's state of health and to reduce the risk of transmission of the virus to others.

To participate in ICOV, patients must be over 18 years of age, have a COVID-19 infection confirmed by a specific test, have clinical manifestations of the infection, and have signed an informed consent. They will then be randomized into 3 treatment groups to ensure the robustness of the study results. The reference group will be treated with LPV/r, according to current recommendations in Côte d'Ivoire. The other 2 groups will be treated with LPV/r + telmisartan and LPV/r + atorvastatin respectively. The treatment will last 10 days and patients will be followed for a total of 28 days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 COVID-19 Drug Treatment Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Severe Acute Respiratory Syndrome Coronavirus 2 Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte d’Ivoire

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years of age.
  • With SARS-CoV-2 infection confirmed by specific PCR.
  • With clinical manifestations of the infection, such as fever or cough, or otolaryngologic (ORL) signs or respiratory difficulties, that started less than 7 days ago.
  • COVID-19 specific treatment-naive.
  • Women of childbearing age should accept the use of mechanical contraception during the study period.
  • Informed consent signed by the patient.

Exclusion criteria

  • Severe form of infection requiring oxygen therapy > 4l/min to achieve oxygen saturation > 94%.
  • Patient whose weight is < 35kg.
  • Pharmacological investigation contraindicating the introduction of a CYP450 inhibitor, in particular the CYP3A4 isoform.
  • Known hypersensitivity to lopinavir, ritonavir, telmisartan, atorvastatin or their excipients.
  • Renal impairment (eGFR <30 mL/min, CKD-EPI formulation).
  • Known cirrhosis.
  • Transaminases > 3N.
  • Bilirubin > 2.6N.
  • Electrocardiogram showing QTc> 500 ms.
  • HIV-infected patient without treatment or treated with protease inhibitors (lopinavir, darunavir, atazanavir).
  • Ongoing exposure to statins.
  • Contraindications to the use of statin:

CPK > 5N, history of rhabdomyolysis or myopathies, increased risk when atorvastatin is administered with strong CYP3A4 inhibitors or transport proteins (cyclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, letermovir, erythromycin, diltiazem, verapamil, fluconazole).

  • Ongoing exposure to sartans.
  • Contraindications to the use of telmisartan:

patient on angiotensin-converting enzyme (ACE) inhibitors, aliskiren or other angiotensin receptor blockers (ARB).

  • Curatorship or guardianship.
  • Pregnancy or breastfeeding.
  • Dementia or any other condition that prevents informed consent.
  • Any reason that, at the discretion of the investigator, would compromise patient safety and cooperation in the trial.

Treatment and study plan

Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet

Drug

2 tablets morning and evening from Day 1 to Day 10

Other names: LPV/r, Aluvia

Telmisartan 40Mg Oral Tablet

Drug

1 tablet daily from Day 1 to Day 10

Other names: TMS, Micardis, Pritor

Atorvastatin 20 Mg Oral Tablet

Drug

1 tablet daily from Day 1 to Day 10

Other names: ATV, Tahor

Primary outcomes

  1. Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11

    Time frame: Day 11

Secondary outcomes

  1. Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28

    Time frame: Day 11 and Day 28

  2. Kinetics of SARS-CoV-2 viral load

    Time frame: Up to Day 28

  3. Death rate at Day 11 and Day 28

    Time frame: Day 11 and Day 28

  4. All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28

    Time frame: Day 28

  5. Time to hospital discharge

    Time frame: Up to Day 28

  6. Duration of oxygen supplementation

    Time frame: Up to Day 28

  7. Prevalence of grade III or IV adverse events

    Time frame: Up to Day 28

  8. Residual concentration of lopinavir, telmisartan and atorvastatin

    Time frame: Up to Day 28

  9. Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes)

    Time frame: Up to Day 28

  10. Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2)

    Time frame: Up to Day 28

  11. Proportion of patients with good results according to HIV status

    Time frame: Up to Day 28

  12. Number of contact cases infected by COVID-19 at Day 28

    Time frame: Day 28

Sponsors and collaborators

Lead sponsor

ANRS, Emerging Infectious Diseases

Other Gov

Collaborators

  • PACCI Program
  • University of Bordeaux

Registry information

Official study title

Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV): a Phase IIb Randomized Clinical Trial

Acronym: INTENSE-COV

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 10, 2020
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.